Study participants
TB, neurologic disease, tuberculosis meningitis
HIV ENCEPHALOPATHY, CRYPTOCOCCAL MENINGITIS, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, TUBERCULOSIS MENINGITIS, CENTRAL NERVOUS SYSTEM TOXOPLASMOSIS
Participants were recruited if they tested positive for HIV at GHESKIO and reported at least 1 TB symptom on a routinely conducted questionnaire, which was conducted in accordance with GHESKIO standard care [Patients were excluded if they had received ART previously, failed to demonstrate preparedness on an ART readiness questionnaire, were treated for TB in the prior year, were pregnant or breastfeeding, had active drug or alcohol use, or a mental condition that would interfere with their ability to adhere to study requirements, or planned to transfer care during the study period. Patients were also excluded if they presented with symptoms consistent with WHO stage 4 neurologic disease (cryptococcal meningitis, tuberculosis meningitis, central nervous system toxoplasmosis, HIV encephalopathy, or progressive multifocal leukoencephalopathy), or WHO “danger signs” of temperature >39 degrees Celsius, pulse >120 beats/minute, respiratory rate >30, or inability to walk unaided. Before undergoing any study procedure, all participants provided written informed consent.